Impact ledger
AstraZeneca PLC (AZN): the developments shaping its investment case
Follow the evidence affecting AstraZeneca PLC's demand outlook. Review the key developments below. Continue in Market Ontology to test your assumptions, examine related opportunities, and save the investment case you want to track.
Research AstraZeneca PLC · $399/mo
Test assumptions, examine opportunities, and save your research.
Material developments
2026-09-29
AstraZeneca and HUTCHMED Submit US NDA for ORPATHYS Plus TAGRISSO in Lung Cancer
Channel: Direct revenue potential from new drug combination approval, expanding market share in NSCLC.
Bullish· 3-12m
2026-09-24 · 6 reports
Hutchmed to Present Phase III Savolitinib NSCLC Trial Results at ESMO 2026 Congress
Channel: Positive clinical trial results for a combination therapy involving a key marketed product (osimertinib/Tagrisso), potentially expanding its addressable market and extending its patent life/market exclusivity.
Bullish· 3-12m
2026-09-29 · 2 reports
AstraZeneca files US FDA NDA for savolitinib combo in MET-driven lung cancer
Channel: Regulatory progress for a novel oncology combination therapy, potentially expanding market share and revenue streams in lung cancer treatment.
Bullish· 3-12m
Evidence affecting valuation assumptions
Each entry names the assumption the evidence touches and how the evidence reads. Direction describes the business mechanism, not a stock-price conclusion.
| Date | Assumption | Direction | Interpretation |
|---|---|---|---|
| 2026-08-06 | share_count | Bullish | Stock component of consideration dilutes existing acquirer holders. |
| 2026-08-06 | net_debt | Bullish | Cash component of consideration is typically debt-funded, raising net debt. |
| 2026-08-06 | revenue | Bullish | Acquisition adds target revenue to acquirer P&L on close. |
Event impact log
22 events mapped to AZN since 2026-08-28. Evidence through 2026-09-29.
| Date | Event | Channel | Direction | Horizon | Impact |
|---|---|---|---|---|---|
| 2026-09-29 | AstraZeneca files US FDA NDA for savolitinib combo in MET-driven lung cancer | Regulatory progress for a novel oncology combination therapy, potentially expanding market share and revenue streams in lung cancer treatment. | Bullish | 3-12m | 0.60 |
| 2026-09-29 | AstraZeneca and HUTCHMED Submit US NDA for ORPATHYS Plus TAGRISSO in Lung Cancer | Direct revenue potential from new drug combination approval, expanding market share in NSCLC. | Bullish | 3-12m | 0.80 |
| 2026-09-29 | AstraZeneca Submits US NDA for Savolitinib and Tagrisso in MET-Driven Lung Cancer | Direct regulatory progress for a key oncology asset, potential for future revenue generation. | Bullish | 3-12m | 0.70 |
| 2026-09-24 | Hutchmed to Present Phase III Savolitinib NSCLC Trial Results at ESMO 2026 Congress | Positive clinical trial results for a combination therapy involving a key marketed product (osimertinib/Tagrisso), potentially expanding its addressable market and extending its patent life/market exclusivity. | Bullish | 3-12m | 0.60 |
| 2026-09-24 | Vertex Inaxaplin Phase IIb Cuts Proteinuria in Kidney Disease Trial | Increased competitive pressure in the kidney disease therapeutic area, potentially impacting future market share for existing or pipeline drugs. | Bearish | 3-12m | 0.30 |
| 2026-09-24 | HUTCHMED and AstraZeneca Present Phase III Lung Cancer Data at ESMO | Positive clinical trial results for a combination therapy involving a key marketed product (osimertinib) and a partnered asset (savolitinib), extending market exclusivity and treatment options. | Bullish | 1-3m | 0.60 |
| 2026-09-24 | HUTCHMED and AstraZeneca present Phase III lung cancer data at ESMO 2026 | Direct positive clinical trial results for a combination therapy involving a key marketed product (osimertinib) and a partner's drug, potentially expanding market opportunities and extending patent life/market exclusivity. | Bullish | 1-3m | 0.75 |
| 2026-09-24 | Ionis Reports Positive Phase III Endpoints in ALS and Kidney Disease | Potential indirect competitive pressure or market dynamics shift in kidney disease treatment. While not directly involved in these specific drugs, AZN has a significant presence in renal and rare disease markets. | watch | 3-12m | 0.30 |
| 2026-09-24 | HUTCHMED and AstraZeneca to Present Savolitinib Phase III NSCLC Data at ESMO | Direct impact from positive clinical trial data presentation for a co-developed asset, reinforcing pipeline strength and potential future revenue contribution. | Bullish | 1-3m | 0.60 |
| 2026-09-24 | HUTCHMED to Present Phase III Savolitinib Lung Cancer Data at ESMO 2026 | Positive clinical trial data for a co-developed oncology asset, contributing to pipeline strength and future revenue potential, though impact is diluted by AZN's larger portfolio. | Bullish | 1-3m | 0.60 |
| 2026-09-21 | Ionis Plunges Over 40% Following Clinical Setbacks in Pelacarsen and Eplontersen | Second-order effect from partnership revenue loss for pelacarsen, though diversified pipeline mitigates overall impact. | Bearish | 3-12m | 0.20 |
| 2026-09-21 | Ionis Plunges Over 40% YTD on Late-Stage Setbacks Despite Bullish Targets | Indirect impact through partnership agreements and potential milestone payments or royalty streams from Ionis's ASO assets. | watch | 3-12m | 0.30 |
| 2026-09-21 | Ionis slides over 40% year-to-date following late-stage clinical setbacks | Partnered drug development. Pelacarsen is a co-development program with AstraZeneca. Setbacks directly impact potential future milestone payments and shared profits. | Bearish | 1-3m | 0.40 |
| 2026-09-21 | Ionis Pharmaceuticals faces pipeline pressure after pelacarsen and eplontersen trial setbacks | Partnership risk. AstraZeneca is a partner for pelacarsen. Setbacks for this drug could reduce future royalty/milestone payments. | Bearish | 3-12m | 0.30 |
| 2026-09-21 | Ionis Pharmaceuticals trades down 40% following late-stage clinical setbacks | Loss of potential future milestone payments and royalties from pelacarsen, which was partnered with AstraZeneca. Reputational risk for partnership efficacy. | Bearish | 3-12m | 0.30 |
| 2026-09-15 | Summit Therapeutics Inc. Announces Updated HARMONi Data Presented at WCLC 2026 | Potential increased competition in the EGFR-mutated NSCLC market, where AstraZeneca's Tagrisso (osimertinib) is a dominant therapy. Ivonescimab's data could challenge or complement existing standards of care. | mixed | 3-12m | 0.30 |
| 2026-08-31 | HUTCHMED and AstraZeneca Announce Positive Phase III SANOVO Trial in NSCLC | Positive clinical trial outcome for a combination therapy involving a key marketed product (Tagrisso) and a partnered asset (Savolitinib), potentially expanding market opportunities and reinforcing Tagrisso's franchise. | Bullish | 1-3m | 0.60 |
| 2026-08-31 | HUTCHMED and AstraZeneca report positive Phase III trial for Orpathys plus Tagrisso | Positive clinical trial outcome for a combination therapy involving a key marketed product (Tagrisso) and a partnered asset (Orpathys), expanding market potential. | Bullish | 3-12m | 0.60 |
| 2026-08-31 | HUTCHMED and AstraZeneca report positive Phase III SANOVO lung cancer trial data | Direct impact from successful clinical trial results for a combination therapy involving one of its blockbuster drugs (osimertinib) and a partner's drug (savolitinib), expanding its market potential. | Bullish | 3-12m | 0.70 |
| 2026-08-31 | HUTCHMED and AstraZeneca Report Positive Phase III SANOVO Trial in China | Direct impact from successful clinical trial results for a co-developed drug, contributing to pipeline strength and potential future revenue streams. | Bullish | 1-3m | 0.60 |
| 2026-08-28 | China NMPA grants conditional approval for HUTCHMED's ATLED in oncology | Potential competitive pressure or partnership opportunities in the FGFR inhibitor space within China. | watch | 3-12m | 0.30 |
| 2026-08-28 | HUTCHMED Receives NMPA Conditional Approval for ATLED in China | Potential competitive pressure in the oncology market, particularly for FGFR2-altered ICC, or potential partnership implications. | watch | 3-12m | 0.20 |
Continue this research
Build your AstraZeneca PLC investment case. Continue from the evidence above, change the assumptions the developments move, and save the work to revisit as the case develops.
This ledger is regenerated from Market Ontology's public event pipeline. View the AZN entity page →